Onbrez Breezhaler (Indacaterol)

Indacaterol, the active ingredient in Onbrez Breezhaler, is a bronchodilator presented as a 150 µg inhalation powder for inhalation use. It provides long‑acting bronchodilation for patients with chronic obstructive pulmonary disease (COPD). GNH USA supplies Onbrez Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Onbrez Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Onbrez Breezhaler contains indacaterol, a long‑acting β2‑agonist that relaxes airway smooth muscle in obstructive lung disease.

- Chronic obstructive pulmonary disease (COPD): improves lung function and reduces symptom burden. - Exercise‑induced bronchoconstriction in COPD: maintains airway patency during physical activity. - Maintenance therapy for COPD: provides once‑daily bronchodilation to help prevent exacerbations.

Adverse reactions reported with indacaterol inhalation are generally mild to moderate.

Common Side Effects: - Cough: transient irritation of the airway. - Throat irritation: mild soreness or dryness. - Nasopharyngitis: upper‑respiratory tract infection symptoms. - Headache: mild to moderate intensity. - Dry mouth: reduced salivation. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of airflow obstruction. - Cardiovascular events: tachycardia, palpitations, or hypertension. - Severe hypersensitivity: rash, angio‑edema, or anaphylaxis. - Severe bronchitis or pneumonia: infection requiring medical attention. - Acute respiratory failure: rapid decline in breathing function. - Chest pain: unexplained thoracic discomfort.

Patients and healthcare providers should consider several safety points when using indacaterol inhalation therapy.

- Assess respiratory status: confirm stable COPD before initiating therapy. - Review cardiovascular history: monitor for tachycardia or hypertension. - Avoid concomitant non‑selective β‑blockers: may reduce bronchodilator effect. - Caution in severe hepatic impairment: dose adjustment may be required. - Educate on proper inhaler technique: ensures adequate drug delivery. - Store below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Indacaterol may interact with other medicines that affect the cardiovascular or respiratory systems.

Major Interactions (Avoid): - Non‑selective β‑blockers: can antagonize bronchodilation and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs): may increase risk of cardiovascular side effects.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypokalaemia, requiring electrolyte monitoring. - Other long‑acting β2‑agonists: additive bronchodilator effect may increase cardiac risk. - Theophylline: potential for increased theophylline plasma concentrations. - Anticholinergic bronchodilators: monitor for additive airway effects. - Cough suppressants containing codeine: may mask bronchospasm symptoms.